AlphAIAlphAI — Financial news for AI agents
sci-tech-today.comOCT 83 min read$NEOG

Neogen Corporation Q1 FY2027 Earnings: Revenue Hits $222.8 Million, Beats Estimates

Neogen Corporation reported Q1 FY2027 revenue of $222.8 million, up 6.5%, and adjusted EPS of $0.08, exceeding estimates. GAAP EPS was negative at $0.05. Shares initially rose 8% after hours. The company raised annual guidance, citing higher margins and positive free cash flow.

Original reporting
sci-tech-today.com
Published Oct 8, 2026, 1:35 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 8, 2026, 2:25 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Neogen Corporation Q1 FY2027 Earnings: Revenue Hits $222.8 Million, Beats Estimates — source image
Source · sci-tech-today.com
Decision brief

The 30-second read

$NEOGBullishMed
01

Why it matters

Earnings beat and guidance raise are fresh primary disclosures, likely to drive short‑term buying interest. The after‑hours rally suggests immediate market enthusiasm, but GAAP loss and cautions on Q2 may cap further gains.

02

Market read

First‑report earnings with beat and guidance lift for a small‑cap biotech; provides a clear trading catalyst.

03

What to watch

Pending genomics divestiture and regulatory review could introduce execution risk not reflected in the earnings beat.

Relevance 8/10Novelty 8/10Timing: after‑hours today

Background

Neogen (NASDAQ:NEOG) provides food safety and animal health diagnostics. The company posted its first quarter FY2027 results, beating revenue and adjusted EPS expectations and raising full‑year guidance.

Company-level read

Ticker impact

$NEOGBullishHigh confidence
Context

Neogen reported Q1 FY2027 revenue of $222.8M beating estimates, adjusted EPS $0.08, and raised FY2027 guidance, causing an 8% after‑hours price jump.

Expected impact

likely modest upside as market prices in the beat and guidance lift, though after‑hours rally may temper on‑day buying.

Evidence & confidence

Revenue beat, adjusted EPS beat, and higher guidance are fresh material; the stock already rallied 8% after‑hours, indicating demand. No major headwinds beyond GAAP loss, so short‑term bias is bullish.

Market effects

Sector

Strengthens the food safety and animal health sector outlook, suggesting peers may benefit from renewed demand for diagnostic products.

Regional

Limited to U.S. and international markets where Neogen operates; no broad regional effect.

Global

Modest; contributes to overall biotech/diagnostics sentiment but unlikely to shift global indices.

Counterpoint

What could challenge this read

GAAP loss and slower Q2 core growth warning could limit upside; the stock may face profit‑taking after the initial rally.

Key entities

  • company
    Neogen Corporation

    NASDAQ‑listed provider of food safety and animal health diagnostic products.

Read at source← All news

StoryNeogen reports Q1 FY2027 revenue growth and raises FY2027 guidance

Also covered by

3 outlets

Related articles

OCT 8
$NEOGMedAI 8/10

Neogen’s Earnings Call Signals Confident Growth Path

Neogen reported Q1 revenue of $222.8M, up 8.1% core, with Food Safety and Animal Safety segments driving growth. Management raised fiscal 2027 guidance to $885M-$890M sales and adjusted EBITDA of $181M-$183M, citing strong demand and operational improvements. The company plans to use genomics divestiture proceeds for debt reduction, aiming for net leverage below 3x.

tipranks.com3 min
OCT 7
$NEOGLow

Neogen Outlines Strategy for Growth, Innovation and Margin Expan

Neogen Corporation (NEOG) outlined its growth strategy at its 2026 Investor Day, targeting high-single-digit to low-double-digit revenue growth, high-50% adjusted gross margin, and 30% adjusted EBITDA margin by FY2031. The company plans to increase R&D investment by 50% in FY2027, aiming for $100M in incremental revenue from new products by FY2031. Neogen also highlighted its data platform, Neogen Analytics, as a key driver of recurring revenue and customer retention.

gurufocus.com3 min
OCT 7
$NEOGHighAI 8/10

Why Are Neogen (NEOG) Shares Soaring Today

Neogen (NEOG) shares rose 14.1% premarket after Q3 2026 results beat expectations, with revenue up 6.5% YoY to $222.8M. The company raised full-year guidance, citing strong growth in indicator testing and Petrifilm. Shares later cooled to $11.79, down 1.7% from the previous close.

finance.yahoo.com2 min
OCT 7
$NEOGMed

Neogen (NEOG) Q1 2027 Earnings Call Transcript

Neogen (NEOG) reported Q1 2027 revenue of $222.8M, up 8.1% year-over-year, driven by commercial excellence. Food Safety segment revenue was $163.2M, with 8.1% core growth. The company is investing in innovation, technology, and operational efficiency to drive long-term growth and margin expansion. Key initiatives include commercial prowess, high-impact innovation, and operational excellence.

finance.yahoo.com3 min
OCT 7
$NEOGHigh

Neogen Q1 Revenue Rises 6.5%; Raises FY27 Outlook

Neogen Corp. (NEOG) reported a 6.5% revenue increase to $222.8M in Q1 FY27, with an adjusted net income of $17.5M. The company raised its FY27 revenue guidance to $885M-$890M and adjusted EBITDA to $181M-$183M. It also announced a collaboration with Hinalea Imaging and plans to sell its Genomics business to Zoetis Inc.

rttnews.com2 min